Advances in oncological treatment of head and neck carcinomas
MUDr. Petra Holečková, Ph.D., MBA1; as. RNDr. Ing. Libor Staněk, PCTM2,3,4
1) Ústav radiační onkologie Nemocnice Na Bulovce a 1. LF UK, Praha
2) Onkologická klinika 1. LF UK, Praha
3) Ústav patologie FN Královské Vinohrady, Praha
4) Chirurgická klinika 3. LF UK, Praha
Carcinoma of the head and neck is a one of cause of cancer-associated illness and death. Most patients present with locoregionally advanced disease, and more than 50% have recurrence within 3 years. Standard of curative care are surgery and radiotherapy. Patients with head and neck carcinoma who progressed or have metastatic disease are treated with platinum-based chemotherapy in combination event. with cetuximab. New treatments agents are checkpoint inhibitors pembrolizumab and nivolumab. Important role in diagnostics and therapy can play molecular biology and genetics.
head and neck carcinomas, HPV, EGFR, cetuximab, checkpoint inhibitors, pembrolizumab, nivolumab, molecular biology
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...